엘앤씨바이오

290650KOSDAQ

52.7 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment17.7 / 25

Momentum3.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 24.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

L&N Bio is a specialist in regenerative medicine, developing and selling human tissue implants and medical devices, along with cosmetic and pharmaceutical businesses. Its flagship product, Acellular Dermal Matrix (MegaDerm), is used for breast reconstruction after cancer treatment, and the company expands its global market by exporting tissue-based medical devices. It aims to grow into a comprehensive healthcare platform through R&D in regenerative medicine.

Number of Employees

155people

Average Salary

49.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

6.06Industry Average 1.200.0Point

5.0x industry avg (risky)

ROE

-55.32Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.94Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 14.6% (declining, 3yr)

Detailed News Sentiment

13 totalPositive 7Neutral 2Negative 4Average Sentiment Score 70.8

Positive
엘앤씨바이오, ‘건(힘줄) ECM’ 조직재건 기술 특허 등록
엘앤씨바이오의 힘줄 ECM 조직재건 기술 특허 등록으로 신약 개발 가능성이 높아져 긍정적인 시장 반응 예상.
Negative
저점인 줄 알았는데…바이오 유증에 개미 '비명'
바이오 관련 기업들의 대규모 유증 발표로 엘앤씨바이오의 주가가 하락 추세에 있다.
Negative
제약·바이오株 개미들 분통…유상증자 후 주가 하락
엘앤씨바이오의 유상증자 결정 이후 주가 하락으로 투자자들의 불만이 증가하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 46,850Won52-week high 118,30052-week low 46,850

1-month return0.0Point

1m -24.44% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

14 totalPositive 2Neutral 12Negative 0

Positive유상증자1차발행가액결정2026-09-02
Positive권리락 (유상증자)2026-09-02
Neutral투자설명서2026-09-02
Neutral[기재정정]주요사항보고서(유무상증자결정)2026-09-02
Neutral[발행조건확정]증권신고서(지분증권)2026-09-02